Galectin Therapeutics (GALT) Non Operating Income (2010 - 2026)
Galectin Therapeutics' quarterly Non Operating Income came in at -$969000.0 in Q1 2026, up 44.12% year-on-year from -$672367.3 in Q1 2025, and up 54.61% quarter-over-quarter from -$2.1 million in Q4 2025.
Galectin Therapeutics has reported Non Operating Income for 17 years, with the latest figure at -$969000.0 in Q1 2026.
- For the quarter ending Q1 2026, Non Operating Income rose 44.12% year-over-year to -$969000.0; the trailing twelve-month figure through Mar 2026 stood at -$10.0 million (down 121.57% YoY), and the FY2025 full-year result was -$10.8 million, down 133.01% from the prior year.
- Non Operating Income for Q1 2026 stood at -$969000.0, up from -$2.1 million in the prior quarter.
- The five-year high for Non Operating Income was $461000.0 in Q4 2024, with the low at -$4.0 million in Q3 2025.
- Average Non Operating Income over 5 years is -$1.2 million, with a median of -$1.1 million recorded in 2024.
- Year-over-year, Non Operating Income plunged 43500.0% in 2023 and surged 205.73% in 2024.
- Tracing GALT's Non Operating Income over 5 years: stood at -$1000.0 in 2022, then sank by 43500.0% to -$436000.0 in 2023, then surged by 205.73% to $461000.0 in 2024, then sank by 563.12% to -$2.1 million in 2025, then surged by 54.61% to -$969000.0 in 2026.
- The last three Non Operating Income figures came in at -$969000.0 (Q1 2026), -$2.1 million (Q4 2025), and -$4.0 million (Q3 2025), per Business Quant data.
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Non Op. Inc. (Qtr) |
|---|---|---|---|---|---|
| 1 | Quantum Biopharma | 1,216,509.61 Bn | 1,216,509.61 Bn | - | - |
| 2 | Alterity Therapeutics | 764,224.41 Bn | 764,224.38 Bn | - | - |
| 3 | Legend Biotech | 2,716.00 Bn | 2,715.71 Bn | 242.10 Mn | - |
| 4 | Nanobiotix | 2,248.83 Bn | 2,248.77 Bn | - | - |
| 5 | Akari Therapeutics | 1,951.18 Bn | 1,951.17 Bn | - | 444,000.00 |
| 6 | Vertex Pharmaceuticals | 113.69 Bn | 106.44 Bn | 2.59 Bn | - |
| 7 | Evaxion A | 64.16 Bn | 64.14 Bn | - | - |
| 8 | Regeneron Pharmaceuticals | 63.94 Bn | 55.18 Bn | 3.31 Bn | 201.20 Mn |
| 9 | Alnylam Pharmaceuticals | 40.13 Bn | 37.12 Bn | 959.66 Mn | -46.98 Mn |
| 10 | Galectin Therapeutics | 165.77 Mn | 151.67 Mn | - | -969,000.00 |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | -969,000.00 |
| Dec 31, 2025 | -2.14 Mn |
| Sep 30, 2025 | -3.99 Mn |
| Jun 30, 2025 | -2.90 Mn |
| Mar 31, 2025 | -1.73 Mn |
| Dec 31, 2024 | 461,000.00 |
| Sep 30, 2024 | -2.15 Mn |
| Jun 30, 2024 | -1.08 Mn |
| Mar 31, 2024 | -1.84 Mn |
| Dec 31, 2023 | -436,000.00 |
| Sep 30, 2023 | -1.26 Mn |
| Jun 30, 2023 | -111,000.00 |
| Mar 31, 2023 | -1.19 Mn |
| Dec 31, 2022 | -1,000.00 |
| Sep 30, 2022 | -475,000.00 |
| Jun 30, 2022 | 49,000.00 |
| Mar 31, 2022 | 3,000.00 |
| Dec 31, 2021 | 204,000.00 |
| Sep 30, 2021 | -276,000.00 |
| Jun 30, 2021 | -256,000.00 |
| Mar 31, 2021 | -21,000.00 |
| Dec 31, 2020 | -20,000.00 |
| Sep 30, 2020 | -17,000.00 |
| Jun 30, 2020 | -12,000.00 |
| Mar 31, 2020 | 28,000.00 |
| Dec 31, 2019 | 51,000.00 |
| Sep 30, 2019 | 79,000.00 |
| Jun 30, 2019 | 22,000.00 |
| Mar 31, 2019 | -8,000.00 |
| Dec 31, 2018 | -65,000.00 |
| Sep 30, 2018 | -72,000.00 |
| Jun 30, 2018 | -81,000.00 |
| Mar 31, 2018 | -80,000.00 |
| Dec 31, 2017 | -9,000.00 |
| Sep 30, 2017 | 6,000.00 |
| Jun 30, 2017 | 6,000.00 |
| Mar 31, 2017 | 9,000.00 |
| Dec 31, 2016 | 8,000.00 |
| Sep 30, 2016 | 11,000.00 |
| Jun 30, 2016 | 12,000.00 |
| Mar 31, 2016 | 14,000.00 |
| Dec 31, 2015 | 12,000.00 |
| Sep 30, 2015 | 12,000.00 |
| Jun 30, 2015 | 14,000.00 |
| Mar 31, 2015 | 14,000.00 |
| Dec 31, 2014 | 3,000.00 |
| Sep 30, 2014 | -41,000.00 |
| Jun 30, 2014 | -54,000.00 |
| Mar 31, 2014 | -266,000.00 |
| Dec 31, 2013 | 5,000.00 |
| Sep 30, 2013 | 3,000.00 |
| Jun 30, 2013 | 3,000.00 |
| Mar 31, 2013 | 5,000.00 |
| Dec 31, 2012 | 6,000.00 |
| Sep 30, 2012 | 207,000.00 |
| Jun 30, 2012 | 8,000.00 |
| Mar 31, 2012 | 3,000.00 |
| Dec 31, 2011 | 4,000.00 |
| Sep 30, 2011 | 5,000.00 |
| Jun 30, 2011 | -136,000.00 |
| Mar 31, 2011 | -379,000.00 |
| Dec 31, 2010 | 561,000.00 |
| Sep 30, 2010 | 103,000.00 |
| Jun 30, 2010 | -304,000.00 |